Serum soluble Fas levels in patients with autoimmune rheumatic diseases

Clinical Biochemistry

Volumn 40, Issue 1-2, 2007, Pages 6-10

  Sahin, M ^a   Aydintug, O ^b   Tunc, S E ^a   Tutkak, H ^b   Naziroglu M ^c  

^a Faculty of Medicine   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Apoptosis; Autoimmune disease; Polymyositis Dermatomyositis; Rheumatoid arthritis; Serum soluble Fas

Indexed keywords

ANTIMALARIAL AGENT; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MALE; MEDICAL ASSESSMENT; OSTEOARTHRITIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RHEUMATIC DISEASE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; ANTIGENS, CD95; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RHEUMATIC DISEASES; SOLUBILITY;

EID: 33845806983     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.09.003     Document Type: Article

References (31)

1. Li N.L., Nie H., Yu O.W., Zhang J.Y., Ma A.L., Shen B.H., et al. Role of soluble Fas ligand in autoimmune diseases. World J. Gastroenterol. 10 (2004) 3151-3156
2. Stummvoll G.H., Aringer M., Smolen J.S., Koller M., Kiener H.P., Steiner C.W., et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39 (2000) 1341-1350
3. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1455
4. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., et al. Protection from Fas mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994) 1759-1762
5. Hao J.H., Ye D.Q., Zhang G.Q., Liu H.H., Dai H., Huang F., et al. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch. Dermatol. Res. 297 (2006) 329-332
6. Bianchi T., Bardazzi F., and Patrizi A. Soluble Fas levels in patients with systemic sclerosis. Arch. Dermatol. Res. 292 (2000) 522-523
7. Nakamura H., Kawakami A., Izumi M., Nakashima T., Takagi Y., Ida H., et al. Detection of the soluble form of Fas ligand (sFasL) and sFas in the saliva from patients with Sjogren's syndrome. Clin. Exp. Rheumatol. 23 (2005) 915
8. Christensson M., Pettersson E., Eneslatt K., Christensson B., Bratt J., Rantapaa-Dahlqvist S., et al. Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J. Clin. Immunol. 22 (2002) 220-227
9. Hasunuma T., Kayagaki N., Asahara H., Motokawa S., Kobata T., Yagita H., et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 40 (1997) 80-86
10. Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., and Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases. Arthritis Rheum. 40 (1997) 1126-1129
11. Ates A., Kinikli G., Turgay M., and Duman M. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 223 (2004) 421-425
12. Goel N., Ulrich D.A., St.Clair E.W., Fleming J.A., Lynch D.H., and Seldin M.F. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum. 38 (1995) 1738-1743
13. Knipping E., Krammer P.H., Onel K.B., Lehman T.J.A., Mysler E., and Elkon K.B. Levels of soluble Fas/APO-1/CD 95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 38 (1995) 1735-1737
14. Tan E.M., Cohen E.S., Fries C.F., Masi A.T., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982) 1271-1277
15. Arnett F.C., Edworthy S.M., Bloch D.A., Mc Shane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
16. Masi A.T. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23 (1980) 581-590
17. Pinals R.S., Masi A.T., and Larsen R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 24 (1981) 1308-1315
18. Kahaleh M.B., Sultany G.I., Smith E.A., Huffstutter J.E., Loadholt B., and LeRoy E.C. A modified scleroderma skin scoring method. Clin. Exp. Rheumatol. 4 (1986) 367-369
19. Fox R.I., Robinson C.A., Curd J.G., Kozin F., and Howell F. Sjögren's syndrome proposed criteria for classification. Arthritis Rheum. 29 (1986) 577-585
20. Bohan A., and Peter J.B. Polymyositis and dermatomyositis. N. Engl. J. Med. 292 (1975) 344-347
21. Altman R. Classification of disease: osteoarthritis. Semin. Arthritis Rheum. 20 Suppl. 2 (1991) 40-47
22. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35 (1992) 630-640
23. Choi J.W. Reference intervals of serum soluble APO-1 (Fas/CD95) concentrations in healthy adults. Ann. Clin. Lab. Sci. 36 (2006) 103-104
24. Sato M., Takemura M., Shinohe R., Koishi H., Morita T., and Seishima M. Clinical significance of serum IL-18 determination in rheumatoid arthritis. Rinsho Byori 52 (2004) 109-114
25. Jodo S., Kobayashi S., Kayagaki N., Ogura N., Feng Y., Amasaki Y., et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin. Exp. Immunol. 107 (1997) 89-95
26. Al Maini M.H., Mountz J.D., Al Mohri H.A., El-Ageb E.M., Al-Riyami B.M., Svenson K.L., et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9 (2000) 132-139
27. Sgonc R., Gruschwitz M.S., Dietrich H., Recheis H., Gershwin M.E., and Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98 (1996) 785-792
28. Wetzig T., Petri J.B., Mittag M., and Haustein U.F. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch. Dermatol. Res. 290 (1998) 187-190
29. Takata-Tomokuni A., Ueki A., Shiwa M., Isozaki Y., Hatayama T., Katsuyama H., et al. Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis. Immunology 116 (2005) 21-29
30. Matsumuro E., Kagami M., Tomioka H., Tanabe E., Sugiyama T., Sueishi M., et al. Expression of ductal Fas in sialoadenitis of Sjögren's syndrome. Clin. Exp. Rheumatol. 14 (1996) 309-311
31. Fujihara T., Takeuchi T., Tsubota K., Kayagaki N., Yagita Y., Okumura K., et al. Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. Clin. Rheumatol. 17 (1998) 496-499